MENU

Stephen C. Rubin, MD

Stephen Rubin, MD

Clinical Locations

Primary Location

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111

About

Treatment Focus

Surgery and chemotherapy for all gynecologic cancers; minimally invasive surgery for gynecologic cancers, precancerous conditions and benign gynecologic conditions

Key Awards

  • Philadelphia Magazine Top Doctors, 1993-2017
  • America’s Top Doctors® 2015-2017 
  • Best Doctors in America® 2014

Treatment Philosophy

I joined Fox Chase Cancer Center in 2014 as chief of the Division of Gynecologic Oncology. I spent the early part of my medical career at Memorial Sloan-Kettering Cancer Center in New York and the Hospital of the University of Pennsylvania, where I was chief of gynecologic oncology. As a gynecologic oncologist, I have extensive training and experience in surgery (including minimally invasive) for gynecologic cancers and for complex benign gynecologic conditions. I also provide the full range of chemotherapy options for gynecologic cancers, giving my patients the continuity of care that comes with multimodal cancer care.

I am delighted to be practicing at Fox Chase, where I offer patients state-of-the-art care, including innovative clinical trials, in a caring, compassionate environment, with all the support services that come from an NCI-designated Comprehensive Cancer Center.

Education and Training

Educational Background

  • Fellow, Gynecologic Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, 1982
  • Resident, Obstetrics & Gynecology, Hospital of the University of Pennsylvania, Philadelphia, PA, 1980
  • MD, University of Pennsylvania School of Medicine, Philadelphia, PA, 1976

Certifications

  • American Board of Obstetrics and Gynecology
  • American Board of Obstetrics and Gynecology, Division of Gynecologic Oncology

Memberships

  • American Association of Gynecologic Laparoscopists
  • American College of Obstetricians and Gynecologists
  • American College of Surgeons
  • American Federation for Clinical Research
  • American Gynecological and Obstetrical Society
  • American Radium Society
  • American Society of Clinical Oncology
  • American Society for Colposcopy and Cervical Cytology
  • Association of Professors of Gynecology and Obstetrics
  • Society of Gynecologic Oncologists
  • Society for Gynecologic Investigation
  • Society of Pelvic Surgeons
  • Society of Surgical Oncology
  • International Gynecologic Cancer Society
  • European Society of Gynecological Oncology
  • Felix Rutledge Society
  • New York Academy of Sciences
  • New York Obstetrical Society
  • New York Gynecological Society
  • Obstetrical Society of Philadelphia
  • Philadelphia Colposcopy Society
  • Philadelphia College of Physicians
  • Mid-Atlantic Gynecologic Oncology Society

Honors & Awards

  • Philadelphia Magazine Top Doctors, 1993-2017
  • America’s Top Doctors® 2015-2017
  • Best Doctors in America® 2014
  • MA honoris causa, University of Pennsylvania, 1994
  • Presidential Award, Society of Gynecologic Oncologists, 1993
  • Boyer Award for Clinical Investigation, Memorial Sloan-Kettering Cancer Center, 1990
  • Clinical Oncology Career Development Award, American Cancer Society, 1987-90
  • Chief Resident's Teaching Award, Medical College of Pennsylvania, 1983
  • Clinical Fellow, American Cancer Society, 1980-82
Patient Stories

Mary Schwarzenberger

Ovarian & Primary Peritoneal Cancer

Mary Schwarzenberger

Ovarian & Primary Peritoneal Cancer

“My doctor told me Dr. Rubin ‘wrote the book’ on gynecologic surgery and was at the top of his class. This was someone he would send his loved ones to, if needed. That was all the endorsement I needed to hear.”

Joan Foley

Ovarian & Primary Peritoneal Cancer

Joan Foley

Ovarian & Primary Peritoneal Cancer

When Joan Foley learned she had ovarian cancer, she did her research and read great things about Dr. Stephen Rubin at Fox Chase Cancer Center. At Fox Chase, Joan underwent surgery less than a week after her initial consultation with Dr. Rubin. Following surgery, she also underwent chemotherapy for 18 weeks. Today, Joan is feeling goos and is back to working as a researcher at a university in Philadelphia. "I recommend that anyone diagnosed with cancer should do their homework and research well-regarded oncologists who have expertise in a specific diagnostic area of cancer," she said. "My family now contributes to a research fellowship program led by Dr. Rubin to train research fellows in the field of gynecologic cancers...Because Fox Chase is a research institution, it offers patients a treatment edge, and research at Fox Chase can inform existing treatment protocols to yield better outcomes now and in the future."

Mary Haspel

Ovarian & Primary Peritoneal Cancer

Mary Haspel

Ovarian & Primary Peritoneal Cancer

Mary Haspel received several false diagnoses for what was first diagnosed as a urinary tract infection. Eventually, after a number of tests, she was diagnosed with ovarian cancer. Mary's doctor referred her to Fox Chase Cancer Center, where she underwent a hysterectomy. The next stage of treatment was an 18-week course of chemotherapy, followed by 12 monthly treatments. The treatment was successful, and Mary returned to her normal life, but decided to retire so she could pursue other interests, such as teaching yoga. In March 2017, she was diagnosed with a small recurrence of cancer, but is responding well to the chemotherapy and feels positive about the outcome.

Lizbeth Brunswick

Ovarian & Primary Peritoneal Cancer

Lizbeth Brunswick

Ovarian & Primary Peritoneal Cancer

Lizbeth Brunswick was 60 years old and had never been in the hospital when she was diagnosed with ovarian cancer in 2014. Her gynecologist recommended she seek treatment with Dr. Stephen Rubin at Fox Chase Cancer Center, where she underwent surgery and an 18-week course of chemotherapy, all while continuing her work life in New York City. In October 2016, she spoke at the Fox Chase Cancer Center Laurel Society event at The Kimmel Center for Performing Arts, where she described not only her experience with cancer treatment at Fox Chase but also her belief in the importance of philanthropy to support cancer research. "I know I would not be where I am today if it weren’t for everyone at Fox Chase," Lizbeth said. "I believe that by giving back, we give others the chance to beat this disease. Without research there is no cure."

Debbie Richards

Ovarian & Primary Peritoneal Cancer

Debbie Richards

Ovarian & Primary Peritoneal Cancer

Debbie did her research and asked a highly regarded gynecologist, “Who would you go to if someone in your family had ovarian cancer?” The answer was Dr. Stephen Rubin.

Research Profile

Research Interests

  • Clinical trials and innovative therapies for gynecologic cancers
Publications

Selected Publications

Resilience, Positive Coping, and Quality of Life Among Women Newly Diagnosed With Gynecological Cancers. Manne SL, Myers-Virtue S, Kashy D, Ozga M, Kissane D, Heckman C, Rubin SC, Rosenblum N. Cancer Nurs. 2015 Sep-Oct;38(5):375-82. doi: 10.1097/NCC.0000000000000215.

Correlation of pelvic magnetic resonance imaging diagnosis with pathology for indeterminate adnexal masses. Haggerty AF, Hagemann AR, Chu C, Siegelman ES, Rubin SC. Int J Gynecol Cancer. 2014 Sep;24(7):1215-21. doi: 10.1097/IGC.0000000000000203. PMID: 25153677

Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente M, Fleming GF, Lim PC, Rubin SC, Katsumata N, Liang SX. J Clin Oncol. 2014 Apr 20;32(12):1210-7. doi: 10.1200/JCO.2013.53.6524. Epub 2014 Mar 17. PMID: 24637999

Paget Cells in Endometrial and Endocervical Curettings in a Patient With Recurrent Vulvar Paget's Disease. Clayton EF, Rubin SC, Dumoff KL. Int J Surg Pathol. 2014 Jun;22(4):374-7. doi: 10.1177/1066896913498819. Epub 2013 Aug 5. PMID: 23918905

Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Chu CS, Boyer J, Schullery DS, Gimotty PA, Gamerman V, Bender J, Levine BL, Coukos G, Rubin SC, Morgan MA, Vonderheide RH, June CH. Cancer Immunol Immunother. 2012 May;61(5):629-41. doi: 10.1007/s00262-011-1081-8. Epub 2011 Oct 22. PMID: 22021066

A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer. Adams SF, Marsh EB, Elmasri W, Halberstadt S, Vandecker S, Sammel MD, Bradbury AR, Daly M, Karlan B, Rubin SC. Gynecol Oncol. 2011 Dec;123(3):486-91. doi: 10.1016/j.ygyno.2011.08.032. Epub 2011 Sep 25. PMID: 21945552

Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma. Hagemann AR, Hagemann IS, Cadungog M, Hwang WT, Patel P, Lal P, Hammond R, Gimotty PA, Chu CS, Rubin SC, Birrer MJ, Powell DJ Jr, Feldman MD, Coukos G. Cancer Biol Ther. 2011 Aug 15;12(4):367-77. Epub 2011 Aug 15. PMID: 21785280

Tissue-based immune monitoring I: tumor core needle biopsies allow in-depth interrogation of the tumor microenvironment. Hagemann AR, Cadungog M, Hagemann IS, Hammond R, Adams SF, Chu CS, Rubin SC, Zhang L, Addya K, Birrer MJ, Gimotty PA, Coukos G. Cancer Biol Ther. 2011 Aug 15;12(4):357-66. Epub 2011 Aug  15. PMID: 21785264

Clinical predictors of bevacizumab-associated gastrointestinal perforation. Tanyi JL, McCann G, Hagemann AR, Coukos G, Rubin SC, Liao JB, Chu CS. Gynecol Oncol. 2011 Mar;120(3):464-9. doi: 10.1016/j.ygyno.2010.11.009. Epub 2010 Dec 17. PMID: 21168199

Vaginal intraepithelial neoplasia (VAIN) after radiation therapy for gynecologic malignancies: a clinically recalcitrant entity. Liao JB, Jean S, Wilkinson-Ryan I, Ford AE, Tanyi JL, Hagemann AR, Lin LL, McGrath CM, Rubin SC. Gynecol Oncol. 2011 Jan;120(1):108-12. doi: 10.1016/j.ygyno.2010.09.005. PMID: 20937524

Additional Publications

PubMed

Connect with Fox Chase